Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Thermo Fisher Scientific Collaborates with Harvard

Thermo Fisher ScientificThermo Fisher Scientific Inc., the world leader in serving science, today announced the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center in collaboration with Massachusetts General Hospital (MGH), Harvard University. Strokes are the leading cause of serious long-term disability in the U.S. The research, conducted using Thermo Scientific mass spectrometers, provides insight into key areas of stroke evaluation and treatment. The research will be previewed at the MSACL conference in San Diego in February, 2011.  

Led by Dr. MingMing Ning, a clinical neurologist and researcher at the Clinical Proteomics Research Center at MGH, the research provides potentially significant new insight into patent foramen ovale (PFO) and its connection with strokes. PFO refers to a congenital heart abnormality which leaves open a passage between the left and right sides of the heart, enabling blood clots to travel from the leg to the brain. With PFO affecting 25 percent of the worldwide population, the potential health impacts are significant. Identification of potential biomarkers in mass spec data derived from the collaborative research provides scientists with new insights into how PFO can be related to strokes. If confirmed, these insights may be important in helping doctors to select the most appropriate treatment for individual PFO stroke patients.  

The collaboration between the BRIMS Center and Harvard University has also led to potential insights in the understanding of tissue plasminogen activator (tPA) in stroke treatment.  tPA is a drug that can be safely administered only within a very short time window after stroke symptoms occur. The treatment, which works by dissolving blood clots, has proven highly effective but involves significant risks. Only 5 percent of patients fit the timeframe criteria within which it is safe to administer tPA. Through the use of mass spectrometry-based proteomics workflows, data from the collaborative research may someday help scientists identify a wider scope of patients who might benefit from tPA.  

Dr Ning comments: "We are now able to conduct research directly at the bedside of acute stroke patients, thanks to the collaboration between Dr. Mary Lopez and her team at the BRIMS Center; Dr. Tom Jacobs at NIH/NINDS; and Dr. Eng H Lo, Dr. Ferdinando Buonanno and Dr. Anne Young at the Clinical Proteomics Research Center at MGH. This was not possible before and has allowed us to build a crucial bridge from research to treatment, enabling us to gather key research information in real-time." 

For more information about Thermo Scientific solutions for proteomic research, please call +1 800-532-4742, email analyze@thermofisher.com or visit www.thermoscientific.com/ms.


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events